JP2014159381A - Ornithine-containing composition for improving body composition - Google Patents
Ornithine-containing composition for improving body composition Download PDFInfo
- Publication number
- JP2014159381A JP2014159381A JP2013029725A JP2013029725A JP2014159381A JP 2014159381 A JP2014159381 A JP 2014159381A JP 2013029725 A JP2013029725 A JP 2013029725A JP 2013029725 A JP2013029725 A JP 2013029725A JP 2014159381 A JP2014159381 A JP 2014159381A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ornithine
- salt
- body composition
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 103
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 title claims abstract description 59
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960003104 ornithine Drugs 0.000 title claims abstract description 53
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 26
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000011701 zinc Substances 0.000 claims abstract description 26
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 19
- 229930003231 vitamin Natural products 0.000 claims abstract description 19
- 235000013343 vitamin Nutrition 0.000 claims abstract description 19
- 239000011782 vitamin Substances 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 27
- 208000004210 Pressure Ulcer Diseases 0.000 abstract description 13
- 230000006872 improvement Effects 0.000 abstract description 8
- 230000002980 postoperative effect Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 24
- 230000037406 food intake Effects 0.000 description 19
- -1 inorganic acid salts Chemical class 0.000 description 17
- 239000000843 powder Substances 0.000 description 14
- 235000016709 nutrition Nutrition 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 11
- 229930003268 Vitamin C Natural products 0.000 description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 235000019154 vitamin C Nutrition 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 206010011985 Decubitus ulcer Diseases 0.000 description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940049920 malate Drugs 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QHNVWXUULMZJKD-UHFFFAOYSA-N 3,4-didehydroretinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C QHNVWXUULMZJKD-UHFFFAOYSA-N 0.000 description 2
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 2
- 229930195715 D-glutamine Natural products 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 235000000112 undernutrition Nutrition 0.000 description 2
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229930000083 3-dehydroretinol Natural products 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical class 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Abstract
Description
本発明は、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を有効成分として含有する体組成改善用組成物に関する。 The present invention relates to a composition for improving body composition comprising ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins as active ingredients.
高齢者においては、様々な生活課題が発生するが、食事もそのうちの一つである。すなわち、一般的には、高齢者は、咀嚼が困難になること、また、淡白な食物への嗜好度が高まることから、肉等の動物性タンパク質や脂質を多く含む食物の摂取量が不足することになる。しかし、これらのタンパク質や脂質の摂取は高齢者の健康維持・向上に必須の栄養成分であることが分かっている。例えば、ある地域における70歳の高齢者の集団について10年間調査し、食習慣と余命の関係を分析した結果、油脂類と牛乳をコンスタントに摂る人ほど余命が長いことが示された（非特許文献１）。また、高齢者600名の食生活について2年間調査を行った結果、肉類や牛乳等の動物性たんぱく質食品と油脂類を多く摂る人ほど、余暇活動や創作等の日常生活を楽しむのに必要な生活機能の低下が抑制されるという報告がある（非特許文献２）。 In the elderly, various life problems occur, and meals are one of them. In other words, in general, elderly people have difficulty in chewing, and their preference for light foods increases, resulting in a shortage of intake of foods rich in animal proteins such as meat and lipids. It will be. However, it is known that intake of these proteins and lipids is an essential nutritional component for maintaining and improving the health of the elderly. For example, a 10-year survey of a group of 70-year-old elderly people in a region analyzed the relationship between dietary habits and life expectancy, and showed that people who constantly consume oils and fats have longer lives (non-patented). Reference 1). In addition, as a result of a two-year survey on the dietary habits of 600 elderly people, people who consume more animal protein foods such as meat and milk and fats and oils are necessary to enjoy leisure activities and daily life such as creative activities. There is a report that a decline in living functions is suppressed (Non-patent Document 2).
このように、食事からのタンパク質・脂質の摂取は高齢者において特に重要である。摂取したタンパク質が体内で活用されているかについては、一般的には血中アルブミン濃度がその指標となる。血中アルブミン値と高齢者の運動能力が関連するという報告を一つ示す。すなわち、平均71歳の自立高齢者約300人について、体力の指標の一つである最大歩行速度の変化を8年間継続的に調査した結果、血清アルブミン値が低い人ほど速度の低下が大きいことが示された（非特許文献３）。 Thus, protein and lipid intake from the diet is particularly important for elderly people. In general, blood albumin concentration is an indicator of whether the ingested protein is utilized in the body. One report shows that blood albumin levels are related to the exercise capacity of the elderly. That is, about 300 independent elderly people with an average of 71 years old, as a result of continuous investigation of changes in maximum walking speed, which is one of the indices of physical fitness, for 8 years, the lower the serum albumin level, the greater the decrease in speed Was shown (Non-patent Document 3).
さらに、低栄養状態に疾患等による入院生活が加味されると、これに運動不足が加わる。運動不足はさらなる食欲の低下を引き起こすことから、栄養状態がさらに悪化し、寝たきり状態に陥ることもある。そこで、最近では、病院や介護施設において、医師・看護師・栄養士らがNutrition Support Team（NST）を結成し、患者の栄養改善に積極的に取り組む動きが広がっており、高齢者の栄養状態維持における食事の重要性が認識されている。 Furthermore, when hospitalization due to diseases or the like is added to the undernutrition state, lack of exercise is added to this. Insufficient exercise causes further loss of appetite, which can further exacerbate nutritional conditions and lead to bedridden conditions. Therefore, recently, doctors, nurses and nutritionists have formed a Nutrition Support Team (NST) in hospitals and nursing homes, and are actively working on improving the nutrition of patients. The importance of diet in Japan is recognized.
低栄養状態を改善するための組成物として、例えば、タンパク質と油脂を含む飲食物が開示されている（特許文献１）。しかし、タンパク質と油脂とを含む飲食物では、従来の飲食物と違いが無い。 As a composition for improving the undernutrition state, for example, a food and drink containing protein and fat is disclosed (Patent Document 1). However, food and drink containing protein and fats and oils are no different from conventional food and drink.
一方で、体内のタンパク質合成を促進するものとして、成長ホルモンがある。成長ホルモンは、その名のとおり、成長期に多く分泌されるホルモンであり、骨や筋肉の成長を促すが、このホルモンは、加齢とともにその分泌量が減少する。 On the other hand, growth hormone is one that promotes protein synthesis in the body. Growth hormone, as the name suggests, is a hormone that is secreted during the growth phase and promotes the growth of bones and muscles, but the secretion of this hormone decreases with age.
オルニチンは、その摂取により、成長ホルモンの分泌を促進することが知られている（非特許文献４）。また、これによる体脂肪率の減少といった体組成の変化（非特許文献５）が報告されていることから、オルニチンを含む食品の摂取により、特に体内の成長ホルモン分泌量が低下している高齢者において、筋肉分解抑制・体組成改善効果が得られる可能性が示唆される。 Ornithine is known to promote the secretion of growth hormone when ingested (Non-patent Document 4). In addition, since changes in body composition such as a decrease in body fat percentage (Non-Patent Document 5) have been reported, elderly people whose growth hormone secretion amount in the body is decreased particularly due to ingestion of food containing ornithine. Suggests the possibility of obtaining an effect of inhibiting muscle degradation and improving body composition.
本発明の目的は、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を有効成分として含有する体組成改善用組成物を提供することにある。 An object of the present invention is to provide a composition for improving body composition comprising ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins as active ingredients.
本発明は、下記の（１）〜（１９）に関する。
（１）オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を有効成分として含有する体組成改善用組成物。
（２）オルニチンまたはその塩が、オルニチンとして、組成物に含有されるタンパク質量（アミノ酸も含む。）の１０〜７０質量％であることを特徴とする（１）記載の体組成改善用組成物。
（３）オルニチンまたはその塩が、オルニチンとして、組成物全量の５〜４５質量％であることを特徴とする（１）または（２）記載の体組成改善用組成物。
（４）オルニチンまたはその塩とグルタミンまたはその塩との重量組成比がオルニチンおよびグルタミンとして１：４〜９：４である（１）から（３）のいずれか記載の体組成改善用組成物。
（５）オルニチンまたはその塩と亜鉛との重量組成比がオルニチンおよび亜鉛として７０：３〜１０：１である（１）から（４）のいずれか記載の体組成改善用組成物。
（６）１回の摂取または投与あたりの量が２．０〜８．０ｇになるように包装されていることを特徴とする（１）記載の体組成改善用組成物。
（７）オルニチンまたはその塩がオルニチンとして８００〜１７００ｍｇ含まれることを特徴とする（６）記載の体組成改善用組成物。
（８）グルタミンまたはその塩がグルタミンとして１００〜２０００ｍｇ含まれることを特徴とする（６）記載の体組成改善用組成物。
（９）亜鉛が０．１〜１５ｍｇ含まれることを特徴とする（６）記載の体組成改善用組成物。
（１０）ビタミン類がビタミンＡおよびビタミンＣからなる群から選ばれる１以上のビタミン類を含有する（６）記載の体組成改善用組成物。
（１１）ビタミンＡが１０〜６００μｇ含まれることを特徴とする（１０）記載の体組成改善用組成物。
（１２）ビタミンＣが２４〜５００ｍｇ含まれることを特徴とする（１０）記載の体組成改善用組成物。
（１３）オルニチンまたはその塩とビタミンＣとの重量組成比がオルニチンとビタミンＣとして３：２〜７：２である（１２）記載の体組成改善用組成物。
（１４）組成物が粉末または顆粒であることを特徴とする（１）から（１３）のいずれか記載の体組成改善用組成物。
（１５）さらに酸味料を含むことを特徴とする（１）から（１４）のいずれか記載の体組成改善用組成物。
（１６）酸味料がクエン酸である（１５）記載の体組成改善用組成物。
（１７）（１）から（１６）のいずれか記載の体組成改善用組成物を含有、混合、溶解させた飲料。
（１８）ｐＨが３．０〜４．０であることを特徴とする（１７）記載の飲料。
（１９）体組成を改善させるための方法であって、体組成を改善させる必要のある対象者に、対象者の体組成を改善させるのに十分な量のオルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を摂取させる、または投与する工程を含む、方法。
The present invention relates to the following (1) to (19).
(1) A composition for improving body composition comprising ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins as active ingredients.
(2) The composition for improving body composition according to (1), wherein ornithine or a salt thereof is 10 to 70% by mass of ornithine as a protein amount (including amino acids) contained in the composition. .
(3) The composition for improving body composition according to (1) or (2), wherein ornithine or a salt thereof is ornithine in an amount of 5 to 45% by mass based on the total amount of the composition.
(4) The composition for improving body composition according to any one of (1) to (3), wherein the weight composition ratio of ornithine or a salt thereof and glutamine or a salt thereof is 1: 4 to 9: 4 as ornithine and glutamine.
(5) The composition for body composition improvement according to any one of (1) to (4), wherein the weight composition ratio of ornithine or a salt thereof and zinc is 70: 3 to 10: 1 as ornithine and zinc.
(6) The body composition improving composition as described in (1), which is packaged so that the amount per ingestion or administration is 2.0 to 8.0 g.
(7) The composition for improving body composition according to (6), wherein ornithine or a salt thereof is contained in an amount of 800 to 1700 mg as ornithine.
(8) The composition for improving body composition according to (6), wherein glutamine or a salt thereof is contained in an amount of 100 to 2000 mg as glutamine.
(9) The body composition improving composition as described in (6), wherein 0.1 to 15 mg of zinc is contained.
(10) The composition for improving body composition according to (6), wherein the vitamin contains one or more vitamins selected from the group consisting of vitamin A and vitamin C.
(11) The composition for improving body composition according to (10), wherein 10 to 600 μg of vitamin A is contained.
(12) The composition for improving body composition according to (10), wherein vitamin C is contained in an amount of 24 to 500 mg.
(13) The composition for improving body composition according to (12), wherein the weight composition ratio of ornithine or a salt thereof and vitamin C is 3: 2 to 7: 2 as ornithine and vitamin C.
(14) The composition for improving body composition according to any one of (1) to (13), wherein the composition is a powder or a granule.
(15) The composition for improving body composition according to any one of (1) to (14), further comprising an acidulant.
(16) The composition for improving body composition according to (15), wherein the acidulant is citric acid.
(17) A beverage comprising, mixing and dissolving the composition for improving body composition according to any one of (1) to (16).
(18) The beverage according to (17), which has a pH of 3.0 to 4.0.
(19) A method for improving body composition, wherein a subject who needs to improve body composition, ornithine or a salt thereof, glutamine or a salt thereof in an amount sufficient to improve the body composition of the subject Ingesting or administering zinc and vitamins.
本発明により、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を有効成分として含有する体組成改善用組成物を提供することができる。該組成物は、褥瘡の予防、抑制、改善、術後回復等として用いることができる。 According to the present invention, a composition for improving body composition comprising ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins as active ingredients can be provided. The composition can be used for prevention, suppression, improvement, postoperative recovery, etc. of pressure ulcers.
本発明で用いられるオルニチンとしては、Ｌ−オルニチンまたはＤ−オルニチンがあげられるが、Ｌ−オルニチンが好ましい。本発明で用いられるオルニチンは、どのような製造法によって得られたものであってもよく、Ｌ−オルニチンの製造法としては、例えば化学合成法［Ｃｏｌｌ．Ｃｚｅｃｈｏｓｌｏｖ．Ｃｈｅｍ．Ｃｏｍｍｕｎ．，２４，１９９３（１９５９） ］、発酵法（特開昭５３−２４０９６号公報、特開昭６１−１１９１９４号公報）等の方法があげられる。 Examples of ornithine used in the present invention include L-ornithine and D-ornithine, with L-ornithine being preferred. Ornithine used in the present invention may be obtained by any production method. Examples of the production method of L-ornithine include chemical synthesis [Col. Czechoslov. Chem. Commun. , 24, 1993 (1959)], fermentation methods (Japanese Patent Laid-Open Nos. 53-24096 and 61-119194), and the like.
また、Ｌ−オルニチンおよびＤ−オルニチンは、シグマ−アルドリッチ社等より購入することもできる。オルニチンの塩としては、例えば酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等があげられる。酸付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α−ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩があげられる。 L-ornithine and D-ornithine can also be purchased from Sigma-Aldrich. Examples of ornithine salts include acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like. Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate And organic acid salts such as gluconate and caprylate.
金属塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、マグネシウム塩、カルシウム塩等のアルカリ土類金属塩、アルミニウム塩、亜鉛塩等があげられる。アンモニウム塩としては、アンモニウム、テトラメチルアンモニウム等の塩があげられる。有機アミン付加塩としては、モルホリン、ピペリジン等の塩があげられる。アミノ酸付加塩としては、グリシン、フェニルアラニン、リジン、アスパラギン酸、グルタミン酸等の塩があげられる。上記のオルニチンの塩のうち、塩酸塩、クエン酸塩、リンゴ酸塩、α−ケトグルタル酸塩、アスパラギン酸塩が好ましく用いられるが、他の塩、または２以上の塩を適宜組み合わせて用いてもよい。 Examples of the metal salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt and zinc salt. Examples of ammonium salts include salts such as ammonium and tetramethylammonium. Examples of the organic amine addition salt include salts of morpholine, piperidine and the like. Examples of amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, glutamic acid and the like. Of the above ornithine salts, hydrochloride, citrate, malate, α-ketoglutarate and aspartate are preferably used, but other salts or two or more salts may be used in appropriate combination. Good.
本発明の組成物中のオルニチンまたはその塩の配合量は、適宜選択されるが、オルニチンとして、組成物に含有されるタンパク質量（アミノ酸も含む。）に対して通常は１０〜７０質量％、好ましくは２０〜６０質量％、特に好ましくは３０〜５０質量％である。 The compounding amount of ornithine or a salt thereof in the composition of the present invention is appropriately selected, but usually 10 to 70% by mass with respect to the amount of protein (including amino acids) contained in the composition as ornithine, Preferably it is 20-60 mass%, Most preferably, it is 30-50 mass%.
本発明の組成物中のオルニチンまたはその塩の配合量は、適宜選択されるが、オルニチンとして、組成物全量に対して通常は５〜４５質量％、好ましくは１５〜３５質量％、特に好ましくは２０〜３０質量％である。 The blending amount of ornithine or a salt thereof in the composition of the present invention is appropriately selected. As ornithine, it is usually 5 to 45% by mass, preferably 15 to 35% by mass, particularly preferably based on the total amount of the composition. It is 20-30 mass%.
本発明で用いられるグルタミンとしては、Ｌ−グルタミンまたはＤ−グルタミンがあげられるが、Ｌ−グルタミンが好ましい。本発明で用いられるグルタミンは、どのような製造法によって得られたものであってもよく、Ｌ−グルタミンの製造法としては、例えばＷＯ２００７／０７４８５７等の方法があげられる。 Examples of glutamine used in the present invention include L-glutamine and D-glutamine, with L-glutamine being preferred. The glutamine used in the present invention may be obtained by any production method, and examples of the production method of L-glutamine include methods such as WO2007 / 074857.
また、Ｌ−グルタミンおよびＤ−グルタミンは、シグマ−アルドリッチ社等より購入することもできる。グルタミンの塩としては、例えば酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等があげられる。酸付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α−ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩があげられる。 L-glutamine and D-glutamine can also be purchased from Sigma-Aldrich. Examples of glutamine salts include acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like. Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate And organic acid salts such as gluconate and caprylate.
本発明の組成物中のオルニチンまたはその塩とグルタミンまたはその塩との重量組成比がオルニチンおよびグルタミンとして、特に限定はないが、１：４〜９：４が好ましく、３：４〜７：４がさらに好ましく、５：４が特に好ましい。 The weight composition ratio of ornithine or a salt thereof and glutamine or a salt thereof in the composition of the present invention is not particularly limited as ornithine and glutamine, but is preferably 1: 4 to 9: 4, and 3: 4 to 7: 4. Is more preferable, and 5: 4 is particularly preferable.
本発明で用いられる亜鉛としては、組成物に亜鉛イオンを供給することができる可食性のものであれば、特に限定はないが、亜鉛を含有する塩や、亜鉛を高含有する酵母等の微生物を挙げることができる。特に好ましい亜鉛イオン添加物としては、グルコン酸亜鉛を挙げることができる。 The zinc used in the present invention is not particularly limited as long as it is edible so that zinc ions can be supplied to the composition. However, a salt containing zinc or a microorganism such as yeast containing a high amount of zinc. Can be mentioned. Particularly preferable zinc ion additives include zinc gluconate.
本発明の組成物中のオルニチンまたはその塩と亜鉛との重量組成比がオルニチンおよび亜鉛として、特に限定はないが、７０：３〜１０：１が好ましく、２０：１〜４０：３がさらに好ましく、５０：３が特に好ましい。 The weight ratio of ornithine or a salt thereof and zinc in the composition of the present invention is not particularly limited as ornithine and zinc, but is preferably 70: 3 to 10: 1, more preferably 20: 1 to 40: 3. 50: 3 is particularly preferred.
本発明で用いられるビタミン類としては、例えばコエンザイムＱ１０、ビタミンＡ、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２、ビタミンＣ、ビタミンE等があげられるが、特にビタミンＡやビタミンＣが好ましい。ビタミンＡとしては、レチノール（ビタミンＡ１）、３−デヒドロレチノール（ビタミンＡ２）、レチナール、３−デヒドロレチナール、レチノイン酸、３−デヒドロレチノイン酸、これらの酢酸エステル、パルミチン酸エステル等の誘導体をあげることができる。ビタミンＣとしては、例えば、Ｌ−アスコルビン酸、Ｌ−アスコルビン酸ナトリウム、Ｌ−アスコルビン酸ステアリン酸エステル等をあげることができる。 Examples of vitamins used in the present invention include coenzyme Q10, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin E and the like, and vitamin A and vitamin C are particularly preferable. Examples of vitamin A include retinol (vitamin A1), 3-dehydroretinol (vitamin A2), retinal, 3-dehydroretinal, retinoic acid, 3-dehydroretinoic acid, their acetates, and palmitic acid derivatives. Can do. Examples of vitamin C include L-ascorbic acid, sodium L-ascorbate, and L-ascorbic acid stearate.
本発明の組成物中のオルニチンまたはその塩とビタミンＣとの重量組成比がオルニチンおよびビタミンＣとして、特に限定はないが、３：２〜７：２が好ましく、２：１〜３：１がさらに好ましく、５：２が特に好ましい。 The weight composition ratio of ornithine or a salt thereof and vitamin C in the composition of the present invention is not particularly limited as ornithine and vitamin C, but is preferably 3: 2 to 7: 2, preferably 2: 1 to 3: 1. More preferred is 5: 2.
本発明の組成物としては、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類をそのまま摂取または投与することも可能であるが、通常各種の製品形態または製剤として提供するのが望ましい。 As the composition of the present invention, ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins can be ingested or administered as they are, but it is usually desirable to provide them in various product forms or preparations.
該製品または製剤は、有効成分としてオルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有するが、更に任意の有効成分を含有していてもよい。また、該製品または製剤は、有効成分を薬理学的に許容される一種またはそれ以上の担体と一緒に混合し、製剤学の技術分野においてよく知られている任意の方法により製造される。 The product or preparation contains ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins as active ingredients, but may further contain any active ingredient. The product or preparation is produced by any method well known in the technical field of pharmaceutics by mixing the active ingredient with one or more pharmaceutically acceptable carriers.
該製品または製剤の摂取または投与形態は、体組成改善に際し最も効果的なものを使用するのが望ましく、経口摂取もしくは投与または、例えば静脈内、腹膜内もしくは皮下投与等の非経口投与をあげることができるが、経口摂取または投与が好ましい。 The intake or administration form of the product or preparation is desirably the most effective in improving body composition, and includes oral intake or administration, or parenteral administration such as intravenous, intraperitoneal or subcutaneous administration. Oral intake or administration is preferred.
摂取または投与する形態または剤形としては、例えば錠剤、散剤、顆粒剤、丸剤、懸濁剤、乳剤、浸剤・煎剤、カプセル剤、ドリンク剤、液剤、エリキシル剤、エキス剤、チンキ剤、流エキス剤等の経口剤、注射剤、点滴剤、クリーム剤、坐剤等の非経口剤のいずれでもよいが、経口剤として好適に用いられる。 Examples of forms or dosage forms for ingestion or administration include tablets, powders, granules, pills, suspensions, emulsions, soaking / decoction, capsules, drinks, liquids, elixirs, extracts, tinctures, fluids Any of oral preparations such as extracts, parenteral preparations such as injections, infusions, creams, suppositories, etc. may be used, but they are preferably used as oral preparations.
摂取または経口投与に適当な、例えばドリンク剤のような液体調製物は、水、蔗糖、ソルビトール、果糖等の糖類、ポリエチレングリコール、プロピレングリコール等のグリコール類、ごま油、オリーブ油、大豆油等の油類、ｐ−ヒドロキシ安息香酸エステル類等の防腐剤、パラオキシ安息香酸メチル等のパラオキシ安息香酸誘導体、安息香酸ナトリウム等の保存剤、ストロベリーフレーバー、ペパーミント等のフレーバー類などを添加して製剤化することができる。 Liquid preparations such as drinks suitable for ingestion or oral administration include water, sucrose, sorbitol, sugars such as fructose, glycols such as polyethylene glycol, propylene glycol, oils such as sesame oil, olive oil, soybean oil And preservatives such as p-hydroxybenzoates, paraoxybenzoic acid derivatives such as methyl paraoxybenzoate, preservatives such as sodium benzoate, and flavors such as strawberry flavor and peppermint. it can.
また、経口摂取または投与に適当な、例えば錠剤、散剤および顆粒剤等は、乳糖、白糖、ブドウ糖、蔗糖、マンニトール、ソルビトール等の糖類、バレイショ、コムギ、トウモロコシ等の澱粉、炭酸カルシウム、硫酸カルシウム、炭酸水素ナトリウム、塩化ナトリウム等の無機物、結晶セルロース、カンゾウ末、ゲンチアナ末等の植物末等の賦形剤、澱粉、寒天、ゼラチン末、結晶セルロース、カルメロースナトリウム、カルメロースカルシウム、炭酸カルシウム、炭酸水素ナトリウム、アルギン酸ナトリウム等の崩壊剤、ステアリン酸マグネシウム、タルク、水素添加植物油、マクロゴール、シリコーン油等の滑沢剤、ポリビニールアルコール、ヒドロキシプロピルセルロース、メチルセルロース、エチルセルロース、カルメロース、ゼラチン、澱粉のり液等の結合剤、脂肪酸エステル等の界面活性剤、グリセリン等の可塑剤などを添加して製剤化することができる。 Also suitable for oral ingestion or administration, such as tablets, powders and granules are saccharides such as lactose, sucrose, glucose, sucrose, mannitol, sorbitol, starch such as potato, wheat, corn, calcium carbonate, calcium sulfate, Inorganic substances such as sodium hydrogen carbonate and sodium chloride, excipients such as crystalline cellulose, plant powder such as licorice powder, gentian powder, starch, agar, gelatin powder, crystalline cellulose, carmellose sodium, carmellose calcium, calcium carbonate, carbonic acid Disintegrants such as sodium hydrogen and sodium alginate, magnesium stearate, talc, hydrogenated vegetable oil, macrogol, silicone oil and other lubricants, polyvinyl alcohol, hydroxypropylcellulose, methylcellulose, ethylcellulose, carmellose, gera Emissions, starch binders glue solution and the like, surfactants such as fatty acid esters can be formulated by adding a plasticizer such as glycerin.
また、経口摂取または投与に適当な製品形態または製剤には、一般に飲食品に用いられる添加剤、例えば甘味料、着色料、保存料、増粘安定剤、酸化防止剤、発色剤、漂白剤、防かび剤、ガムベース、苦味料、酵素、光沢剤、酸味料、調味料、乳化剤、強化剤、製造用剤、香料、香辛料抽出物等が添加されてもよい。 In addition, product forms or preparations suitable for oral ingestion or administration include additives generally used in foods and drinks such as sweeteners, coloring agents, preservatives, thickening stabilizers, antioxidants, color formers, bleaching agents, An antifungal agent, gum base, bittering agent, enzyme, brightener, acidulant, seasoning, emulsifier, reinforcing agent, manufacturing agent, fragrance, spice extract and the like may be added.
また、経口摂取または投与に適当な製品形態または製剤は、例えば摂取期間、摂取回数、摂取量など摂取当たりの単位包装形態の錠剤、散剤、顆粒剤、丸剤、懸濁剤、乳剤、浸剤・煎剤、カプセル剤、ドリンク剤、液剤、エリキシル剤、エキス剤、チンキ剤、流エキス剤に加工製造することができる。例えば「１回摂取当たりの単位包装形態」とは、１回あたりに摂取する量が予め定められた形態であり、「１週間〜３ヶ月間当たりの単位包装形態」とは、１週間〜３ヶ月間で摂取する量が含まれている形態である。単位包装形態としては、例えば、パック、包装、ボトル等で一定量を規定する形態が挙げられる。 In addition, product forms or preparations suitable for oral ingestion or administration include, for example, tablets, powders, granules, pills, suspensions, emulsions, soaking agents, etc. It can be processed and manufactured into a decoction, capsule, drink, liquid, elixir, extract, tincture, and flow extract. For example, “unit packaging form per ingestion” is a form in which the amount to be ingested per time is determined in advance, and “unit packaging form per week to 3 months” is from 1 week to 3 It is a form that includes the amount consumed every month. As a unit packaging form, the form which prescribes | regulates a fixed quantity with a pack, packaging, a bottle etc. is mentioned, for example.
例えば「１回摂取当たりの単位包装形態」としては、製品形態または製剤が顆粒剤であるような場合オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物を顆粒化した組成物として１回摂取あたりの形態でパック等に入れられている形態が挙げられる。 For example, “unit packaging form per ingestion” is a composition obtained by granulating a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins when the product form or preparation is a granule. The form put in the pack etc. with the form per ingestion as a thing is mentioned.
また、例えば顆粒化した組成物として１回摂取あたりの形態でパック等に入れられている形態の場合、適宜選択されるが、顆粒化した組成物を適当な量の飲料などに含有、混合、溶解しやすい通常は２．０ｇ〜８．０ｇ、好ましくは３．０〜７．０ｇ、特に好ましくは４．０〜６．０ｇである形態があげられる。 In addition, for example, in the case of a form that is put in a pack or the like in a form per ingestion as a granulated composition, it is selected as appropriate, but the granulated composition is contained in an appropriate amount of beverage, mixed, The form which is easy to melt | dissolve normally is 2.0g-8.0g, Preferably it is 3.0-7.0g, Most preferably, it is 4.0-6.0g.
本発明の組成物の摂取または投与回数は、摂取または投与形態、摂取または投与を必要とする者の年齢、体重、治療すべき症状の性質もしくは重篤度により異なるが、通常、成人一日当り、必要とされる本発明の組成物量を１〜５回、好ましくは２回摂取または投与する。 The ingestion or administration frequency of the composition of the present invention varies depending on the ingestion or administration form, the age of the person who needs the ingestion or administration, the body weight, the nature or severity of the condition to be treated, The required amount of the composition of the present invention is taken or administered 1 to 5 times, preferably twice.
オルニチンまたはその塩の摂取または投与量は、適宜選択されるが、１回の摂取または投与あたりオルニチンとして、通常は８００〜１７００ｍｇ、好ましくは１０００〜１５００ｍｇ、特に好ましくは１２００〜１３００ｍｇである。８００ｍｇ未満の場合はオルニチンに由来する効果が生じにくくなる可能性があり、１７００ｍｇより多い場合はその他の本発明に含まれるタンパク質（アミノ酸も含む）と合計した窒素摂取量が高くなるため、、体に与える窒素負荷の観点から好ましくない可能性がある。 The intake or dose of ornithine or a salt thereof is appropriately selected, but is usually 800 to 1700 mg, preferably 1000 to 1500 mg, particularly preferably 1200 to 1300 mg as ornithine per one intake or administration. If it is less than 800 mg, the effects derived from ornithine may be less likely to occur, and if it is more than 1700 mg, the total nitrogen intake with other proteins (including amino acids) included in the present invention will be high. May be undesirable from the viewpoint of nitrogen load applied to
グルタミンまたはその塩の摂取または投与量は、適宜選択されるが、１回の摂取または投与あたりグルタミンとして、通常は１００〜２０００ｍｇ、好ましくは５００〜１６００ｍｇ、特に好ましくは９００〜１２００ｍｇである。１００ｍｇ未満の場合はグルタミンに由来する効果が生じにくくなる可能性があり、２０００ｍｇより多い場合はその他の本発明に含まれるタンパク質（アミノ酸も含む）と合計した窒素摂取量が高くなるため、体に与える窒素負荷の観点から好ましくない可能性がある。 The intake or dose of glutamine or a salt thereof is appropriately selected, but is usually 100 to 2000 mg, preferably 500 to 1600 mg, particularly preferably 900 to 1200 mg as glutamine per intake or administration. If it is less than 100 mg, the effects derived from glutamine may be less likely to occur, and if it is more than 2000 mg, the total amount of nitrogen intake with other proteins (including amino acids) included in the present invention will be high. This may be undesirable from the viewpoint of the nitrogen load to be applied.
亜鉛の摂取または投与量は、適宜選択されるが、１回の摂取または投与あたり通常は０．１〜１５ｍｇ、好ましくは３．０〜１２．０ｍｇ、特に好ましくは６．０〜９．０ｍｇである。０．１ｍｇ未満の場合は亜鉛に由来する創傷治癒効果が生じにくくなる可能性があり、１５ｍｇより多い場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量を超えることになる。 The intake or dose of zinc is appropriately selected, but is usually 0.1 to 15 mg, preferably 3.0 to 12.0 mg, particularly preferably 6.0 to 9.0 mg per intake or administration. is there. If it is less than 0.1 mg, there is a possibility that the wound healing effect derived from zinc is less likely to occur, and if it is more than 15 mg, it exceeds the amount of nutrients contained in the daily intake standard amount that is the standard for nutritional functional foods It will be.
ビタミン類の摂取または投与量は、適宜選択されるが、ビタミンＡの場合１回あたり通常は１０〜６００μｇ（６００μｇは２０００ＩＵ相当）、好ましくは１００〜４００μｇ、特に好ましくは１３５〜２００μｇである。１０μｇ未満の場合はビタミンＡに由来するコラーゲン合成や上皮生成の効果が生じにくくなる可能性があり、１３５μｇ未満の場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量４５０ＩＵを下回り、６００μｇより多い場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量２０００ＩＵを超えることになる。 The intake or dosage of vitamins is appropriately selected. In the case of vitamin A, it is usually 10 to 600 μg (600 μg is equivalent to 2000 IU), preferably 100 to 400 μg, particularly preferably 135 to 200 μg per time. If it is less than 10 μg, the effects of collagen synthesis and epithelial generation derived from vitamin A may be less likely to occur. If it is less than 135 μg, the nutritional components contained in the daily intake standard amount that is the standard for nutritional functional foods If the amount is less than 450 IU and more than 600 μg, it will exceed the amount of nutrient component 2000 IU included in the daily intake standard amount that is the standard for nutritional functional foods.
ビタミンＣの摂取または投与量は１回のあたり通常は２４〜１０００ｍｇ、好ましくは１００〜７５０ｍｇ、特に好ましくは１５０〜５００ｍｇである。２４ｍｇ未満の場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量を下回りビタミンＣに由来する効果が生じにくくなる可能性があり、１００ｍｇで厚生労働省が定める１日当たりの栄養所要量所要量を満たす。１５０〜５００ｍｇは褥瘡発生時の１日の必要量として適当である。１０００ｍｇより多い場合は栄養機能食品の規格基準である１日当たりの摂取目安量に含まれる栄養成分量を超えることになる。 The intake or dose of vitamin C is usually 24-1000 mg, preferably 100-750 mg, particularly preferably 150-500 mg per dose. If it is less than 24 mg, it may be less than the amount of nutrients contained in the daily intake standard amount, which is the standard for functional nutritional foods, and it may be difficult to produce an effect derived from vitamin C. Meet nutritional requirements. 150 to 500 mg is appropriate as a necessary daily amount at the time of pressure ulcer development. When it is more than 1000 mg, it exceeds the amount of nutrient components contained in the daily intake standard amount that is the standard for functional nutritional foods.
摂取または投与期間は、特に限定されないが、通常は１日間〜１年間、好ましくは１週間〜３ヶ月間である。 The intake or administration period is not particularly limited, but is usually 1 day to 1 year, preferably 1 week to 3 months.
本発明の体組成改善用組成物は、褥瘡の予防、抑制、改善、および術後回復に適用できる。 The composition for improving body composition of the present invention can be applied to the prevention, suppression, improvement and postoperative recovery of pressure ulcers.
また本発明は、体組成を改善させるための方法を包含する。本発明の方法は、体組成を改善させる必要のある対象者に、対象者の体組成を改善させるのに十分な量のオルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を摂取させる、または投与する工程を含む。 The present invention also includes a method for improving body composition. The method of the present invention allows a subject in need of improving body composition to ingest sufficient amounts of ornithine or salt thereof, glutamine or salt thereof, zinc and vitamins to improve the subject's body composition. Or a step of administering.
以下に、実施例を挙げて本発明をさらに詳細に説明するが、本発明はこれらにより限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
オルニチン含有粉末の製造
表１記載の処方で常法により粉末を製造した。成分の配合はＡ群とＢ群は同時に混合を行い、その後Ｃ群の成分を配合し５ｇとした。Ａ群とＢ群を同時に混合を行うことにより、飲料などへの溶解性が良い粉末が得られることが分かった。
オルニチン含有飲料の製造
実施例１で得た粉末５ｇを１０、５０、８０、１００、１２０、２４０、５００ｍｌの飲料水に配合し、それぞれについて溶解性および味の評価を行った。
Production of ornithine-containing beverage 5 g of the powder obtained in Example 1 was blended in 10, 50, 80, 100, 120, 240, and 500 ml of drinking water, and the solubility and taste of each were evaluated.
溶解性の評価は、１：溶解せず沈殿が生じる、２：ある程度溶解しているが、若干溶け残りがある、３：溶解しており、特に問題にならない、４：溶解している。５：極めて良好に溶解している、の５段階で評価した。 The evaluation of the solubility is as follows: 1: dissolution does not occur, precipitation occurs, 2: dissolution occurs to some extent, but there is a little undissolved, 3: dissolution does not cause any problem, 4: dissolution occurs. 5: Evaluated in 5 grades: very good dissolution.
味の評価は、１：極めて良くない、２：良くない、３：普通であり、特に問題でない、４：良好である。５：極めて良好である、の５段階で評価した。
表２に示すように、１０ｍｌ未満の場合は組成物を溶解させにくくなり、５０ｍｌ以上は問題なく溶解した。また、味の観点からは８０〜２４０ｍｌにおいて良好に摂取できた。 As shown in Table 2, when the amount was less than 10 ml, it was difficult to dissolve the composition, and 50 ml or more was dissolved without any problem. Moreover, it was able to ingest well in 80-240 ml from a viewpoint of taste.
オルニチン含有清涼飲料の製造
実施例１で得た粉末５ｇを１００ｍｌのスポーツドリンク、紅茶（ストレートティー）に配合した。それぞれについて、溶解性・味は良好であり（実施例２と同様の評価で、スポーツドリンクは溶解性３、味３、紅茶は溶解性３、味３、であった。）、特に問題なく清涼飲料水に配合して摂取することができた。
Production of ornithine-containing soft drink 5 g of the powder obtained in Example 1 was blended into 100 ml of sports drink and black tea (straight tea). About each, solubility and taste are favorable (As the same evaluation as Example 2, sports drink was solubility 3, taste 3, and black tea was solubility 3, taste 3.) It was possible to mix and drink with drinking water.
下記に、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類の体組成改善効果を調べた試験例を示す。 Below, the test example which investigated the body composition improvement effect of ornithine or its salt, glutamine or its salt, zinc, and vitamins is shown.
試験例 Shea分類ステージII以上の褥瘡を有する被験者に、通常の食事に加えて、実施例１で得た本発明組成物の粉末５ｇを1包として、これを1日2包（朝夕食事、1包ずつ）、8週間にわたり摂取させた。なお、被験者の年齢や症状等は、表３のとおりである。
図１に示すように、本発明組成物を８週間摂取させたところ、全被験者において試験開始前と比べて褥瘡の進行度を示す指標であるDESIGN-Rが改善した。 As shown in FIG. 1, when the composition of the present invention was ingested for 8 weeks, DESIGN-R, which is an index showing the progress of pressure ulcer, in all subjects was improved compared to before the start of the test.
また、図２および図３に示すように、体タンパク質異化マーカーである3-メチルヒスチジン量の減少に加え、血中プレアルブミン値は、摂取開始時と比較して、摂取４週目および８週目で高値を示した。 Moreover, as shown in FIG. 2 and FIG. 3, in addition to the decrease in the amount of 3-methylhistidine which is a somatic protein catabolism marker, the blood prealbumin level was compared with that at the start of ingestion at 4th and 8th weeks of ingestion. The eye showed a high price.
さらに、図４に示すように、男性に比べて褥瘡の進行度が比較的軽度であった女性においては、摂取開始前と比べて、摂取終了時である８週目における血中アルブミン値が有意に改善していた。 Furthermore, as shown in FIG. 4, the blood albumin level at the end of ingestion at the 8th week is significant in women whose acne progression was relatively mild compared to men, compared to before the start of ingestion. It was improved.
以上の結果のとおり、本発明の組成物は、栄養状態に問題があることが示唆される褥瘡患者の体タンパク合成を促進することにより、褥瘡部位の治癒、また、体組成の改善を成し得ることが実証された。 As described above, the composition of the present invention promotes body protein synthesis in patients with pressure ulcers that are suggested to have problems with nutritional status, thereby healing the pressure ulcer site and improving body composition. Proven to get.
本発明により、褥瘡の予防、抑制、改善や術後回復等の体組成の改善に有用な、オルニチンまたはその塩、グルタミンまたはその塩、亜鉛およびビタミン類を含有する組成物を提供することができる。
According to the present invention, it is possible to provide a composition containing ornithine or a salt thereof, glutamine or a salt thereof, zinc and vitamins, which is useful for improving body composition such as prevention, suppression, improvement and postoperative recovery of pressure ulcers. .
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013029725A JP2014159381A (en) | 2013-02-19 | 2013-02-19 | Ornithine-containing composition for improving body composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013029725A JP2014159381A (en) | 2013-02-19 | 2013-02-19 | Ornithine-containing composition for improving body composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017089288A Division JP6391066B2 (en) | 2017-04-28 | 2017-04-28 | Ornithine-containing composition for improving body composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014159381A true JP2014159381A (en) | 2014-09-04 |
| JP2014159381A5 JP2014159381A5 (en) | 2016-04-07 |
Family
ID=51611405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013029725A Pending JP2014159381A (en) | 2013-02-19 | 2013-02-19 | Ornithine-containing composition for improving body composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2014159381A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021050244A (en) * | 2021-01-07 | 2021-04-01 | 株式会社東洋新薬 | Anti-fatigue agent |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001510145A (en) * | 1997-07-14 | 2001-07-31 | エヌ・ヴイ・ヌートリシア | Nutritional composition containing methionine |
| WO2004052125A1 (en) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Beverage containing amino acid and method of diminishing bitterness of amino acid |
| WO2005023021A1 (en) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | Diet food |
| JP2006342148A (en) * | 2005-05-13 | 2006-12-21 | Kyowa Hakko Kogyo Co Ltd | Oral medicament for improvement in going to sleep or waking |
| JP2007055992A (en) * | 2004-11-02 | 2007-03-08 | Ajinomoto Co Inc | Medicament for perioperative patient |
| WO2007142286A1 (en) * | 2006-06-07 | 2007-12-13 | Kyowa Hakko Bio Co., Ltd. | Fatigue-reducing agent |
| JP2008073007A (en) * | 2006-09-25 | 2008-04-03 | Kyowa Hakko Kogyo Co Ltd | Vinegar acidity suppressing method |
| WO2008072725A1 (en) * | 2006-12-15 | 2008-06-19 | Kyowa Hakko Bio Co., Ltd. | Composition containing agaricus blazei murill |
| JP2008214232A (en) * | 2007-03-02 | 2008-09-18 | Kyowa Hakko Kogyo Co Ltd | Collagen synthesis promoter |
| JP2011120479A (en) * | 2009-12-08 | 2011-06-23 | Kirin Holdings Co Ltd | Basic amino acid-containing packaged beverage |
-
2013
- 2013-02-19 JP JP2013029725A patent/JP2014159381A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001510145A (en) * | 1997-07-14 | 2001-07-31 | エヌ・ヴイ・ヌートリシア | Nutritional composition containing methionine |
| WO2004052125A1 (en) * | 2002-12-06 | 2004-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Beverage containing amino acid and method of diminishing bitterness of amino acid |
| WO2005023021A1 (en) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | Diet food |
| JP2007055992A (en) * | 2004-11-02 | 2007-03-08 | Ajinomoto Co Inc | Medicament for perioperative patient |
| JP2006342148A (en) * | 2005-05-13 | 2006-12-21 | Kyowa Hakko Kogyo Co Ltd | Oral medicament for improvement in going to sleep or waking |
| WO2007142286A1 (en) * | 2006-06-07 | 2007-12-13 | Kyowa Hakko Bio Co., Ltd. | Fatigue-reducing agent |
| JP2008073007A (en) * | 2006-09-25 | 2008-04-03 | Kyowa Hakko Kogyo Co Ltd | Vinegar acidity suppressing method |
| WO2008072725A1 (en) * | 2006-12-15 | 2008-06-19 | Kyowa Hakko Bio Co., Ltd. | Composition containing agaricus blazei murill |
| JP2008214232A (en) * | 2007-03-02 | 2008-09-18 | Kyowa Hakko Kogyo Co Ltd | Collagen synthesis promoter |
| JP2011120479A (en) * | 2009-12-08 | 2011-06-23 | Kirin Holdings Co Ltd | Basic amino acid-containing packaged beverage |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021050244A (en) * | 2021-01-07 | 2021-04-01 | 株式会社東洋新薬 | Anti-fatigue agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10136669B2 (en) | Method for decreasing visceral fat or increasing energy consumption | |
| US7744930B2 (en) | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass | |
| US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
| JP5507802B2 (en) | Muscle aging inhibitor | |
| JP5085541B2 (en) | Fatigue reducing agent | |
| JP2011098896A (en) | Composition for reducing uric acid value | |
| US20160367529A1 (en) | Debility preventative | |
| US10064835B2 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
| JP5053535B2 (en) | Oral for improving sleep or waking up | |
| CN1835752B (en) | Multivitamin syrup for children or young adults | |
| JP6391066B2 (en) | Ornithine-containing composition for improving body composition | |
| JP2014159381A (en) | Ornithine-containing composition for improving body composition | |
| Brophy et al. | Clinical drug therapy for Canadian practice | |
| JP2021100421A (en) | Composition for improving liver function, and food composition for improving liver function | |
| WO2018123873A1 (en) | Composition for promoting perspiration | |
| JP4847732B2 (en) | Cold remedy | |
| EP4137206A1 (en) | Agent for improving quality of sleep | |
| JP4435882B2 (en) | Alcohol absorption inhibiting composition | |
| US10639328B1 (en) | Compositions and methods for reducing hyperglycemia and treating diabetes | |
| JP2008031080A (en) | Lipid utilization-promoting composition | |
| JP5997425B2 (en) | Ornithine-containing composition | |
| JP2022144737A (en) | Composition for preventing increase or decrease of resting energy consumption and composition for preventing decrease or increase of respiratory quotient | |
| JPWO2016152706A1 (en) | Kidney function improving agent | |
| JP2008074733A (en) | Composition for improving endurance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20130304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161208 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170208 |